We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
Read MoreHide Full Article
Inovio Pharmaceuticals, Inc. (INO - Free Report) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001. The study was conducted to evaluate the company’s Ebola DNA vaccine, INO-4212. The company has enrolled an additional 125 patients in the study.
The decision to expand the enrollment came after positive initial safety and immune response data was received from the first set of 75 healthy volunteers. The initial 75-patient stage of the study evaluated INO-4212 in muscle and skin in five study arms in two and three doses, of which one included Inovio’s DNA-based IL-12 immune activator.
Inovio’s share price movement shows that the stock has underperformed the Zacks classified Medical-Biomedical/Genetics industry so far this year. To be precise, the stock lost 11.3% during this period compared with the industry’s increase of 2.6%.
Coming back to the latest news, the EBOV-001 study demonstrated robust immune responses with favorable safety profile in expanded clinical study. It showed that 95% of the subjects generated an Ebola-specific antibody immune response with the mean antibody titer superior to those reported from viral vector-based Ebola vaccines.
Inovio plans to meet with regulators to discuss the next step for INO-4212 in 2017. The company’s decision is supported by encouraging data from the EBOV-001 study and positive preliminary preclinical data from several animal species.
We remind investors that the company was awarded a $45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches for Ebola. The Inovio-led consortium is taking a multi-faceted approach to develop treatments for the prevention of Ebola.
We note that Inovio is not the only company taking steps to curb this lethal disease in the absence of an approved vaccine or treatment. Peers like GlaxoSmithKline plc (GSK - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co., Inc. (MRK - Free Report) are also developing Ebola vaccines.
In fact, Merck’s Ebola Zaire vaccine candidate, V920, received Breakthrough Therapy status from the FDA. The European Medicines Agency provided the candidate PRIME (PRIority MEdicines) status in Jul 2016. Apart from Ebola vaccines, the company is working on the development of Middle East respiratory syndrome/MERS (GLS-5300) virus.
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
Inovio Pharmaceuticals, Inc. (INO - Free Report) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001. The study was conducted to evaluate the company’s Ebola DNA vaccine, INO-4212. The company has enrolled an additional 125 patients in the study.
The decision to expand the enrollment came after positive initial safety and immune response data was received from the first set of 75 healthy volunteers. The initial 75-patient stage of the study evaluated INO-4212 in muscle and skin in five study arms in two and three doses, of which one included Inovio’s DNA-based IL-12 immune activator.
Inovio’s share price movement shows that the stock has underperformed the Zacks classified Medical-Biomedical/Genetics industry so far this year. To be precise, the stock lost 11.3% during this period compared with the industry’s increase of 2.6%.
Coming back to the latest news, the EBOV-001 study demonstrated robust immune responses with favorable safety profile in expanded clinical study. It showed that 95% of the subjects generated an Ebola-specific antibody immune response with the mean antibody titer superior to those reported from viral vector-based Ebola vaccines.
Inovio plans to meet with regulators to discuss the next step for INO-4212 in 2017. The company’s decision is supported by encouraging data from the EBOV-001 study and positive preliminary preclinical data from several animal species.
We remind investors that the company was awarded a $45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches for Ebola. The Inovio-led consortium is taking a multi-faceted approach to develop treatments for the prevention of Ebola.
We note that Inovio is not the only company taking steps to curb this lethal disease in the absence of an approved vaccine or treatment. Peers like GlaxoSmithKline plc (GSK - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co., Inc. (MRK - Free Report) are also developing Ebola vaccines.
In fact, Merck’s Ebola Zaire vaccine candidate, V920, received Breakthrough Therapy status from the FDA. The European Medicines Agency provided the candidate PRIME (PRIority MEdicines) status in Jul 2016.
Apart from Ebola vaccines, the company is working on the development of Middle East respiratory syndrome/MERS (GLS-5300) virus.
Inovio Pharmaceuticals, Inc. Price
Inovio Pharmaceuticals, Inc. Price | Inovio Pharmaceuticals, Inc. Quote
Zacks Rank
Inovio currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>